Shots:

• The termination of 2014 deal- is based on evaluation of portfolio and prioritization of assets within Janssen’s portfolio
• Janssen to support Geron involving transfer of ongoing clinical trials- regulatory- medical affairs- manufacturing and preclinical activities for 12 months and supply imetelstat for clinical manufacturing for up to 24 months
• Imetelstat is currently evaluated in IMbark P-II & IMerge P-II for r/r Myelofibrosis and Myelodysplastic syndromes respectively. Geron further plans to initiate IMerge P-III for Imetelstat for Myelodysplastic syndromes

Ref: Geron | Image: Janssen